RemeGen Biosciences to Present New Data Updates in ACR 2022 – QNT Press Release

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2022 /PRNewswire/ — RemeGen Co., Ltd., a leading biopharmaceutical company with fully integrated capabilities in research and discovery, clinical development, manufacturing, and commercialization of biologic drugs, will join the event of the American College of Rheumatology (ACR) 2022 , hosted from November 10th to 14th. This event will present Telitacicept phase III clinical trial data on Systematic lupus erythematosus (SLE) and data from the phase II clinical trial for Sjorgren’s syndrome.

About Telitacicept

Telitacicept is a novel fusion protein composed of a transmembrane activator and CAML interactor (TACI) and the Fc portion of IgG, which targets and neutralizes B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL). BLyS and APRIL are both involved in the development of B cells from pre-B lymphocytes to mature B cells and ultimately to plasma cells, the professional cells producing antibodies, as well as in the co-stimulation of T-cell proliferation under certain conditions. Telitacicept blocks BLyS and APRIL from binding to BAFF-R, BCMA, and TACI receptors expressed on the B-cell surface, suppressing the BLyS and APRIL signaling, and inhibiting the development and survival of mature …

Full story available on

Source link

Recommended For You

About the Author: News Center